Mara Aspinall has long been a leader in precision medicine, championing diagnostics as vital to better treatments and saving lives. She built Genzyme Genetics into the nation’s top testing business, later acquired by LabCorp for $1 billion, and led Ventana (now Roche Tissue Diagnostics) in pioneering companion diagnostics. As co-founder of BlueStone Venture Partners and partner at Illumina Ventures, she continues shaping the field. She also publishes the Diagnostics Year in Review, serves on multiple boards, and co-founded ASU’s School of Biomedical Diagnostics. This episode explores both her vision for testing and her journey to becoming a transformative leader.
Produced and hosted by Jonathan D. Grinstein, PhD
Audio mixed and mastered by David Mosely
Brought to you by Inside Precision Medicine (SAGE Publishing)
","author_name":"Inside Precision Medicine"}